PVNS stands for pigmented villonodular synovitis, a condition in which the synovium (the thin tissue lining inside a joint) grows abnormally, forming tumor-like nodules. It affects roughly 1.8 people per million, making it quite rare. Despite the word “tumor,” PVNS is not cancer. It’s a benign but locally destructive process that can damage cartilage and bone if left untreated. The condition is now formally classified under a broader name: tenosynovial giant cell tumor, or TGCT.
What Happens Inside the Joint
In a healthy joint, the synovium produces a small amount of fluid that lubricates and nourishes the cartilage. In PVNS, a genetic glitch causes some synovial cells to overproduce a signaling protein called colony-stimulating factor 1 (CSF1). That protein acts like a chemical beacon, attracting waves of immune cells, particularly macrophages, into the joint lining. These recruited cells pile up alongside the abnormal synovial tissue, forming thickened, nodular growths.
The “pigmented” part of the name comes from hemosiderin, an iron-containing compound left behind when blood breaks down inside the joint. Hemosiderin stains the overgrown tissue a brownish or rust color, which is visible both during surgery and on imaging. The combination of inflammatory cell buildup, repeated small bleeds, and progressive tissue thickening is what gradually erodes cartilage and bone over time.
Localized vs. Diffuse Forms
PVNS comes in two distinct patterns, and the distinction matters because it shapes both treatment and outlook.
Localized PVNS involves a single nodule, either within one area of a joint or along a tendon sheath. It causes pain and swelling that can be quite significant, sometimes with mechanical symptoms like locking, catching, or a feeling of joint instability. This form generally responds well to surgical removal and rarely comes back afterward.
Diffuse PVNS spreads across the entire joint lining. Symptoms tend to develop gradually: persistent pain, swelling, stiffness, and sometimes spontaneous bleeding into the joint space (hemarthrosis) with little or no injury to explain it. This form is more aggressive and harder to treat. Even after surgery, the recurrence rate sits around 10% and can reach as high as 30%.
Who Gets PVNS
PVNS most commonly affects young adults and tends to strike the large joints of the limbs. The knee accounts for about 80% of cases, the hip about 15%, with the remainder scattered across the ankle, shoulder, elbow, and rarely the spine. Men and women are affected at similar rates. Because the condition is so uncommon and its symptoms overlap with more familiar problems like meniscus tears or arthritis, diagnosis is often delayed.
How PVNS Is Diagnosed
MRI is the key tool for identifying PVNS. The hemosiderin deposits that give the tissue its characteristic brown color also create a distinctive pattern on imaging: the affected tissue appears dark on virtually all MRI sequences because iron disrupts the magnetic signal. On a specific type of MRI scan called gradient-echo, the iron deposits create what radiologists call a “blooming effect,” where the dark areas appear to spread or bloom outward. This combination of findings is highly suggestive of PVNS and often allows doctors to make a confident diagnosis before any tissue is removed. A biopsy or surgical specimen ultimately confirms it.
Treatment Options
Surgery is the primary treatment for both forms. The procedure, called synovectomy, involves removing as much of the abnormal synovial tissue as possible. For localized PVNS, this is often straightforward and can sometimes be done arthroscopically. Recurrence after complete removal of a localized nodule is uncommon.
Diffuse PVNS presents a bigger challenge because the abnormal tissue coats the entire joint, making it difficult to remove every trace. Some centers use a staged approach, combining open and arthroscopic surgery, sometimes followed by radiation therapy directed at the joint to reduce the chance of regrowth. One study of this combined strategy for diffuse PVNS of the knee reported a recurrence rate of about 8.6% at an average of 10 years, with satisfactory long-term function.
For cases where surgery would cause significant functional loss or severe complications, newer drug therapies now exist. Because PVNS is driven by overactive CSF1 signaling, medications that block the CSF1 receptor can shrink the abnormal tissue without surgery. The FDA has approved targeted therapies for adults with symptomatic TGCT who aren’t good candidates for surgical resection. These drugs work by cutting off the chemical signal that recruits immune cells into the joint, essentially starving the growths of the cellular reinforcements they depend on.
Long-Term Outlook
PVNS is not life-threatening, but it can be joint-threatening. Left untreated, the chronic inflammation and repeated bleeding erode cartilage and bone, eventually leading to secondary osteoarthritis. In severe or recurrent cases, joint damage can progress to the point where joint replacement becomes necessary. This is especially relevant for diffuse PVNS in weight-bearing joints like the knee and hip, where the destructive potential is highest and recurrence is more likely.
With appropriate treatment, most people with localized PVNS do well and return to normal activity. Diffuse PVNS requires closer long-term monitoring, with periodic MRI scans to catch any regrowth early. The availability of targeted drug therapies has expanded options for people whose disease recurs or whose anatomy makes repeat surgery risky, offering a way to control the condition that didn’t exist a decade ago.